{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:16:12Z","timestamp":1790615772744,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0536-y","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T13:17:13Z","timestamp":1494249433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients"],"prefix":"10.1186","volume":"36","author":[{"given":"Renata A.","family":"Tassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Todeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cappella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ardighieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moris","family":"Cadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bandiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Santonocito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore D.","family":"Capoluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Pecorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Bignotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Odicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Ravaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"key":"536_CR1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih I. The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory. Am J Surg Pathol. 2010;34:433\u201343.","journal-title":"Am J Surg Pathol"},{"key":"536_CR2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/B0-32-301089-X\/50010-6","volume-title":"Epithelial Ovarian Cancer. Clinical Gynecologic Oncology","author":"PJ DiSaia","year":"2002","unstructured":"DiSaia PJ, Creasman WT. Epithelial Ovarian Cancer. Clinical Gynecologic Oncology. St. Louis: Mosby Year Book, Inc; 2002. p. 185\u2013206."},{"issue":"Suppl 10:x111-7","key":"536_CR3","first-page":"PMID: 22987944","volume":"23","author":"J Prat","year":"2012","unstructured":"Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23(Suppl 10:x111-7):PMID: 22987944.","journal-title":"Ann Oncol"},{"issue":"12","key":"536_CR4","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M K\u00f6bel","year":"2008","unstructured":"K\u00f6bel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5(12):e232.","journal-title":"PLoS Med"},{"key":"536_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020712-163949","volume":"9","author":"NN Nik","year":"2014","unstructured":"Nik NN, Vang R, Shih IM, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol. 2014;9:27\u201345.","journal-title":"Annu Rev Pathol"},{"key":"536_CR6","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"536_CR7","doi-asserted-by":"publisher","first-page":"CD006910","DOI":"10.1002\/14651858.CD006910.pub2","volume":"7","author":"TA Lawrie","year":"2013","unstructured":"Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;7:CD006910. doi: 10.1002\/14651858.CD006910.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"536_CR8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14656566.2016.1165205","volume":"17","author":"J McLachlan","year":"2016","unstructured":"McLachlan J, Banerjee S. Olaparib for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 2016;17:995\u20131003.","journal-title":"Expert Opin Pharmacother"},{"key":"536_CR9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137\u201354.","journal-title":"Cancer Discov"},{"key":"536_CR10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1593\/neo.04277","volume":"6","author":"C Pilarsky","year":"2004","unstructured":"Pilarsky C, Wenzig M, Specht T, Saeger HD, Gr\u00fctzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6:744\u201350.","journal-title":"Neoplasia"},{"key":"536_CR11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.bbagrm.2014.09.016","volume":"1839","author":"S Zona","year":"2014","unstructured":"Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta. 2014;1839:1316\u201322.","journal-title":"Biochim Biophys Acta"},{"key":"536_CR12","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1515\/BC.2007.159","volume":"388","author":"I Wierstra","year":"2007","unstructured":"Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388:1257\u201374.","journal-title":"Biol Chem"},{"key":"536_CR13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ncb0205-108","volume":"7","author":"RH Costa","year":"2005","unstructured":"Costa RH. FoxM1 dances with mitosis. Nat Cell Biol. 2005;7:108\u201310.","journal-title":"Nat Cell Biol"},{"key":"536_CR14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"536_CR15","doi-asserted-by":"crossref","first-page":"e23790","DOI":"10.1371\/journal.pone.0023790","volume":"6","author":"GT Lok","year":"2011","unstructured":"Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY. Aberrant activation of ERK\/FOXM1 signaling cascade triggers the cell migration\/invasion in ovarian cancer cells. PLoS One. 2011;6:e23790.","journal-title":"PLoS One"},{"key":"536_CR16","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.18632\/oncotarget.2957","volume":"6","author":"WT Chiu","year":"2015","unstructured":"Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, et al. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 2015;6:2349\u201365.","journal-title":"Oncotarget"},{"issue":"11","key":"536_CR17","doi-asserted-by":"crossref","first-page":"e113478","DOI":"10.1371\/journal.pone.0113478","volume":"9","author":"F Zhao","year":"2014","unstructured":"Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, et al. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS One. 2014;9(11):e113478.","journal-title":"PLoS One"},{"issue":"5","key":"536_CR18","doi-asserted-by":"crossref","first-page":"e96989","DOI":"10.1371\/journal.pone.0096989","volume":"9","author":"J Zhou","year":"2014","unstructured":"Zhou J, Wang Y, Wang Y, Yin X, He Y, Chen L, et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One. 2014;9(5):e96989.","journal-title":"PLoS One"},{"key":"536_CR19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1479-5876-12-134","volume":"12","author":"N Wen","year":"2014","unstructured":"Wen N, Wang Y, Wen L, Zhao SH, Ai ZH, Wang Y, et al. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer. J Transl Med. 2014;12:134.","journal-title":"J Transl Med"},{"key":"536_CR20","first-page":"1857","volume":"27","author":"Y Ning","year":"2012","unstructured":"Ning Y, Li Q, Xiang H, Liu F, Cao J. Apoptosis induced by 7-difluoromethoxyl-5,4'-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells. Oncol Rep. 2012;27:1857\u201364.","journal-title":"Oncol Rep"},{"key":"536_CR21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/bjc.2013.126","volume":"108","author":"DS Tan","year":"2013","unstructured":"Tan DS, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer. 2013;108:1553\u20139.","journal-title":"Br J Cancer"},{"key":"536_CR22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419\u201323.","journal-title":"Int J Gynecol Cancer"},{"key":"536_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1359-6349(15)70004-2","volume":"12","author":"N Colombo","year":"2014","unstructured":"Colombo N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJC Suppl. 2014;12:7\u201312.","journal-title":"EJC Suppl"},{"key":"536_CR24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2006.03.056","volume":"103","author":"E Bignotti","year":"2006","unstructured":"Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol. 2006;103:405\u201316.","journal-title":"Gynecol Oncol"},{"key":"536_CR25","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1111\/jcmm.12927","volume":"20","author":"E Bignotti","year":"2016","unstructured":"Bignotti E, Calza S, Tassi RA, Zanotti L, Bandiera E, Sartori E, et al. Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. J Cell Mol Med. 2016;20:2341\u20138.","journal-title":"J Cell Mol Med"},{"key":"536_CR26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"issue":"3","key":"536_CR27","doi-asserted-by":"crossref","first-page":"e4849","DOI":"10.1371\/journal.pone.0004849","volume":"4","author":"E Gemenetzidis","year":"2009","unstructured":"Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One. 2009;4(3):e4849.","journal-title":"PLoS One"},{"issue":"6","key":"536_CR28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/cyto.990050611","volume":"5","author":"A Bertuzzi","year":"1984","unstructured":"Bertuzzi A, Gandolfi A, Germani A, Span\u00f2 M, Starace G, Vitelli R. Analysis of DNA synthesis rate of cultured cells from flow cytometric data. Cytometry. 1984;5(6):619\u201328.","journal-title":"Cytometry"},{"key":"536_CR29","doi-asserted-by":"crossref","first-page":"7.34.1","DOI":"10.1002\/0471142956.cy0734s72","volume":"72","author":"P Cappella","year":"2015","unstructured":"Cappella P, Gasparri F, Pulici M, Moll J. Cell Proliferation Method: Click Chemistry Based on BrdU Coupling for Multiplex Antibody Staining. Curr Protoc Cytom. 2015;72:7.34.1\u201317.","journal-title":"Curr Protoc Cytom"},{"key":"536_CR30","doi-asserted-by":"crossref","unstructured":"Cappella P, Moll J. Assessment of Cell Cycle Inhibitors by Flow Cytometry. INTECH Open Access Publisher. 2011.","DOI":"10.5772\/29128"},{"key":"536_CR31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00749656","volume":"17","author":"A Bollea","year":"1995","unstructured":"Bollea A, Masseroli M, Nicotra A, Beccaglia P, Sen S, Erba E, Balconi G. Automatic quantitation of cell colonies on petri dishes by computerized image analysis. Cytotechnology. 1995;17:185\u201391.","journal-title":"Cytotechnology"},{"key":"536_CR32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"P Andersen","year":"1982","unstructured":"Andersen P, Gill R. Cox\u2019s regression model for counting processes, a large sample study. Ann Stat. 1982;10:1100\u201320.","journal-title":"Ann Stat"},{"key":"536_CR33","first-page":"15","volume":"21","author":"M Rota","year":"2015","unstructured":"Rota M, Antolini L, Valsecchi MG. Optimal cut-point definition in biomarkers: the case of censored failure time outcome. BMC Med Res Methodol. 2015;21:15\u201324.","journal-title":"BMC Med Res Methodol"},{"key":"536_CR34","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.18632\/oncotarget.4546","volume":"6","author":"CJ Barger","year":"2015","unstructured":"Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, et al. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget. 2015;6:27613\u201327.","journal-title":"Oncotarget"},{"key":"536_CR35","first-page":"4835","volume":"20","author":"M Broggini","year":"2000","unstructured":"Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 2000;20:4835\u201340.","journal-title":"Anticancer Res"},{"key":"536_CR36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/PGP.0b013e3182063e71","volume":"30","author":"YH Lee","year":"2011","unstructured":"Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, et al. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol. 2011;30:205\u201317.","journal-title":"Int J Gynecol Pathol"},{"key":"536_CR37","first-page":"95","volume":"4","author":"K Shigemasa","year":"1997","unstructured":"Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, et al. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig. 1997;4:95\u2013102.","journal-title":"J Soc Gynecol Investig"},{"key":"536_CR38","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.4161\/cc.4.11.2152","volume":"4","author":"I Bae","year":"2005","unstructured":"Bae I, Rih JK, Kim HJ, Kang HJ, Haddad B, Kirilyuk A, et al. BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle. 2005;4:1641\u201366.","journal-title":"Cell Cycle"},{"issue":"2","key":"536_CR39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.yexcr.2013.10.022","volume":"320","author":"S Chukkapalli","year":"2014","unstructured":"Chukkapalli S, Amessou M, Dilly AK, Dekhil H, Zhao J, Liu Q, Bejna A, et al. Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. Exp Cell Res. 2014;320(2):233\u201346.","journal-title":"Exp Cell Res"},{"issue":"1","key":"536_CR40","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00242.2005","volume":"290","author":"N Ishimura","year":"2006","unstructured":"Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2006;290(1):G129\u201336.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"536_CR41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/B978-0-12-407190-2.00016-2","volume":"119","author":"I Wierstra","year":"2013","unstructured":"Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191\u2013419.","journal-title":"Adv Cancer Res"},{"key":"536_CR42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ygyno.2011.05.003","volume":"122","author":"H Itamochi","year":"2011","unstructured":"Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, et al. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011;122:641\u20137.","journal-title":"Gynecol Oncol"},{"key":"536_CR43","doi-asserted-by":"crossref","first-page":"20801","DOI":"10.18632\/oncotarget.4600","volume":"6","author":"L Yang","year":"2015","unstructured":"Yang L, Fang D, Chen H, Lu Y, Dong Z, Ding HF, et al. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget. 2015;6:20801\u201312.","journal-title":"Oncotarget"},{"key":"536_CR44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.oraloncology.2010.03.022","volume":"46","author":"A Waseem","year":"2010","unstructured":"Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol. 2010;46:536\u201342.","journal-title":"Oral Oncol"},{"key":"536_CR45","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/MCB.01068-06","volume":"27","author":"Y Tan","year":"2007","unstructured":"Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007;27:1007\u201316.","journal-title":"Mol Cell Biol"},{"key":"536_CR46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccr.2014.03.017","volume":"25","author":"A Aytes","year":"2014","unstructured":"Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014;25:638\u201351.","journal-title":"Cancer Cell"},{"key":"536_CR47","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ygyno.2015.06.025","volume":"138","author":"J Erriquez","year":"2015","unstructured":"Erriquez J, Becco P, Olivero M, Ponzone R, Maggiorotto F, Ferrero A, et al. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. Gynecol Oncol. 2015;138:627\u201333.","journal-title":"Gynecol Oncol"},{"key":"536_CR48","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3892\/or.2016.4585","volume":"35","author":"R Zhang","year":"2016","unstructured":"Zhang R, Shi H, Ren F, Li X, Zhang M, Feng W, Jia Y. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells. Oncol Rep. 2016;35:2466\u201372.","journal-title":"Oncol Rep"},{"key":"536_CR49","doi-asserted-by":"crossref","first-page":"17134","DOI":"10.4238\/2015.December.16.13","volume":"14","author":"ZM Chen","year":"2015","unstructured":"Chen ZM, Shi HR, Li X, Deng YX, Zhang RT. Downregulation of MACC1 expression enhances cisplatin sensitivity in SKOV-3\/DDP cells. Genet Mol Res. 2015;14:17134\u201344.","journal-title":"Genet Mol Res"},{"issue":"12","key":"536_CR50","doi-asserted-by":"crossref","first-page":"e52578","DOI":"10.1371\/journal.pone.0052578","volume":"7","author":"DW Chan","year":"2012","unstructured":"Chan DW, Hui WW, Cai PC, Liu MX, Yung MM, Mak CS, et al. Targeting GRB7\/ERK\/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. PLoS One. 2012;7(12):e52578.","journal-title":"PLoS One"},{"issue":"1","key":"536_CR51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5483\/BMBRep.2014.47.1.069","volume":"47","author":"J Li","year":"2014","unstructured":"Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L, et al. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep. 2014;47(1):33\u20138.","journal-title":"BMB Rep"},{"key":"536_CR52","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.4049\/jimmunol.1400201","volume":"193","author":"M Gil","year":"2014","unstructured":"Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, et al. CXCL12\/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 2014;193:5327\u201337.","journal-title":"J Immunol"},{"key":"536_CR53","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370\u20136.","journal-title":"Gynecol Oncol"},{"key":"536_CR54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-014-0117-2","volume":"31","author":"H Shen","year":"2014","unstructured":"Shen H, Cai M, Zhao S, Wang H, Li M, Yao S, et al. CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma. Med Oncol. 2014;31:117.","journal-title":"Med Oncol"},{"key":"536_CR55","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/ijc.27980","volume":"132","author":"T Abdel-Fatah","year":"2013","unstructured":"Abdel-Fatah T, Sultana R, Abbotts R, Hawkes C, Seedhouse C, Chan S, et al. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. Int J Cancer. 2013;132:2778\u201386.","journal-title":"Int J Cancer"},{"key":"536_CR56","doi-asserted-by":"crossref","first-page":"e1006410","DOI":"10.1371\/journal.pgen.1006410","volume":"12","author":"AJ Hartlerode","year":"2016","unstructured":"Hartlerode AJ, Willis NA, Rajendran A, Manis JP, Scully R. Complex Breakpoints and Template Switching Associated with Non-canonical Termination of Homologous Recombination in Mammalian Cells. PLoS Genet. 2016;12:e1006410.","journal-title":"PLoS Genet"},{"key":"536_CR57","doi-asserted-by":"crossref","first-page":"e31761","DOI":"10.1371\/journal.pone.0031761","volume":"7","author":"M Halasi","year":"2012","unstructured":"Halasi M, Gartel AL. Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One. 2012;7:e31761.","journal-title":"PLoS One"},{"key":"536_CR58","first-page":"127","volume":"8","author":"K Bixel","year":"2015","unstructured":"Bixel K, Hays JL. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med. 2015;8:127\u201335.","journal-title":"Pharmgenomics Pers Med"},{"key":"536_CR59","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","volume":"25","author":"K Gudmundsdottir","year":"2006","unstructured":"Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864\u201374.","journal-title":"Oncogene"},{"key":"536_CR60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-14-179","volume":"14","author":"A Miyasaka","year":"2014","unstructured":"Miyasaka A, Oda K, Yuji Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014;14:179.","journal-title":"BMC Cancer"},{"key":"536_CR61","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","volume":"7","author":"B Stordal","year":"2013","unstructured":"Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al. BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 2013;7:567\u201379.","journal-title":"Mol Oncol"},{"key":"536_CR62","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11684-012-0228-0","volume":"6","author":"F Zhao","year":"2012","unstructured":"Zhao F, Lam EW. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med. 2012;6:376\u201380.","journal-title":"Front Med"},{"key":"536_CR63","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1016\/j.bmc.2015.06.002","volume":"23","author":"Y Chen","year":"2015","unstructured":"Chen Y, Ruben EA, Rajadas J, Teng NN. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer. Bioorg Med Chem. 2015;23:4576\u201382.","journal-title":"Bioorg Med Chem"},{"key":"536_CR64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7150\/thno.13178","volume":"6","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, et al. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics. 2016;6:219\u201330.","journal-title":"Theranostics"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T09:37:16Z","timestamp":1659001036000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0536-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0536-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]},"article-number":"63"}}